Patrick Kenney

Urologic oncologist; healthcare administration

[Yale Urology @Yale_Urology]

Yale Urology is seeking a PGY-3 resident to join our program starting July 1, 2026. We offer exceptional surgical training, high-volume operative experience, all subspecialties, diverse practice settings, research opportunities, and career mentorship. 🧵1 of 2

[Yale Cancer Center @YaleCancer]

.@BraunMDPhD and colleagues tested a “live tumor fragment” lab assay/elive platform using biopsies to predict response to ICI. In a small validation (20 pts later treated with ICI) the Elephas score correctly flagged 82% of responders and 100% of non-responders, including 2 responders missed by standard biomarkers. Larger validation is ongoing. #ASCO26 @SmilowCancer @ASCO @OncoAlert

[Yale Cancer Center @YaleCancer]

.@BraunMDPhD & Dr. Zachary Yochum @YaleHemOnc at #ASCO26: Spatial multi-omics mapping of #kidney tumors showed aggressive rhabdoid/sarcomatoid regions are rich in immune cells, with T cells that appear both activated and exhausted. These findings may help explain why some high-risk tumors still respond to checkpoint immunotherapy. @ASCO @SmilowCancer @OncoAlert

[Soki Kashima @KashimaMDPhD]

Thank you for featuring our work. Huge appreciation to all collaborators, patients and their families!
@DrChoueiri @YaleMed @kidneycan @OncoAlert @syudaikouhou @urol_jua

[Yale Cancer Center @YaleCancer]

At #ASCO26, @kashimamdphd @BraunMDPhD share why some #kidneycancer tumors don’t respond to immunotherapy despite having plenty of T cells. Research found many T cells are “exhausted” and unable to fight cancer effectively, likely due to TGF-β signaling. Blocking TGF-β1 helped restore T cell activity, pointing to a potential new way to overcome resistance. @ASCO @SmilowCancer @OncoAlert

[Mark Lewis, MD, FASCO @marklewismd]

As many other oncologists will also attest, we were taught this was a dead end

It was, dogmatically, never going to work — kras was too much of a “greasy ball” to be targeted

And yet here we are, with truly meaningful survival curves👇

Inspiration on multiple levels #ASCO26

[David Braun @BraunMDPhD]

We are hiring! We are specifically looking for a postgraduate associate - someone who has recently finished university and is ultimately looking to apply to medical school or graduate school.

It is a TWO YEAR clinical/translational position, where you will be interacting closely with patients, involved in translational clinical trials, and working hands on in the lab and with clinical databases.

The ideal candidate is a great communicator, organized, and enthusiastic about patient-oriented clinical and lab research. You will get dedicated mentoring not just on the science and clinic, but also on career/professional development as well.

We are looking for someone to start ASAP! More information here:
https://t.co/RgV4lJw4OM

Please help to spread the word and RT!
@DrChoueiri @VanAllenLab @tompowles1 @YaleCancer @YaleMed @SmilowCancer @kidneycan @OncoAlert @OncLive @KidneyCancer @A_P_S_A @cure_today @yalepathology @Yale_Urology @DrYukselUrun @MarkDSiegel1 @OncBrothers @DrKarineTawagi

[Patrick Kenney @PatrickKenneyMD]

@CanesDavid @Figure_robot What do you feel is the aspect of surgery that inherently requires a human? Decisions, technical mastery, dexterity, & “experience” may at some point favor non-human intelligence & autonomous robots. But there’s more to surgery than those things! Something wonderful will be lost.

[Patrick Kenney @PatrickKenneyMD]

@DrJeanLefebvre @OuestFrance À part les aiguilles évidemment

[Patrick Kenney @PatrickKenneyMD]

Ok
As long as we’re on the topic — masses shouldn’t be described in an imaging report as being “inseparable” from an adjacent organ. That means something different to surgeons!

[𝙳𝚊𝚟𝚒𝚍 𝙲𝚊𝚗𝚎𝚜 @CanesDavid]

🚨Radiology twitter:

STONE(S) in URETER:

My view is the word "nonobstructing" should never be used.

A ureteral stone may have no associated hydro because:

1. It truly is letting urine by

2. It's intermittently obstructing, and you happened to catch it after the upper tract decompressed

3. The patient is trying to die, septic, in shock, not making urine. 💀☠️

Words matter because the non urology care team sees the word "nonobstructing" as "not a problem" and may not consult urology.

Anyone disagree with this? Would love to see alternate perspectives.

[Patrick Kenney @PatrickKenneyMD]

If patients can’t complete the intervention it would stand to reason that the intervention does not work…

[Ryan @reallyoptimized]

@EricTopol Total fail, Eric.

The increase in volume was negligible between control and intercen, and the intervention group was 40% below the recommended guideline.

This trial only showed that compliance is difficult.

[Patrick Kenney @PatrickKenneyMD]

@CanesDavid Yeah that’s the same thing. An intervention that patients can’t complete is an intervention that doesn’t work.

[Patrick Kenney @PatrickKenneyMD]

@CanesDavid The long awaited return of UroList!

[Patrick Kenney @PatrickKenneyMD]

@CanesDavid I remember a certain attending calling me Aesop (“Aesop, Zoom!”) during cases when I was holding camera as a visiting student and intern. Felt like a compliment at the time. 😂

[Albany Med Health System @AlbanyMed]

Welcome to the new chair of Albany Medical Center Urology, Dr. Lara MacLachlan, who specializes in urogynecology and reconstructive pelvic surgery. https://t.co/T1PJW5D2YN

[Columbia Urology @ColumbiaUrology]

YES!

Bursting with pride to see our 2013 residency alumna Dr. Lara MacLachlan @MacLachlanLara named CHAIR of @AlbanyMedUro !!

They could not have chosen a better leader.

#roots @SWIUorg @sufu @AmerUrological @AlbanyMed @LaheyUro

[Toni Choueiri, MD @DrChoueiri]

State-of-the-art talk from Le @BraunMDPhD on anti tumor immunity in RCC @BrighamMedRes Medical grand round.
Walking us through the full arc of the field and investigations over the years:

1. Systemic therapy landscape overview —> ICIs have been transformative, but many patients still do not benefit.
2. Determinants of anti-tumor immunity, including PBRM1 and 9p21.3 deletions.
3. Progressive CD8 exhaustion with advancing disease, M2 like TAM programs, and CD8 TAM interaction signature linked to worse outcomes.
4. Exceptional responders and the weight of TLS and humoral immunity.
5. The future ==> personalized medicine with neoantigen vaccination.

@DanaFarber_GU @Yale @YaleMed @MGBResearchNews @MassGenBrigham

#RCC #Immunotherapy #CancerImmunology

[Toni Choueiri, MD @DrChoueiri]

4/ Our very own @BraunMDPhD’s personalized neoantigen vaccine in high-risk ccRCC in @Nature (Work from #WuLab @DanaFarber who pioneered that technology). Hits driver mutations (VHL, PBRM1, BAP1, KDM5C, PIK3CA) & generates durable T-cell expansion and tumor recognition. 0/9 recurrences at ~40 months. Promising adjuvant therapy in RCC!
@DanaFarber @DanaFarber_GU @Yale

https://t.co/BdbKJqMKOw

[Daniel Shapiro @d_shapiro1]

Sincere congratulations to my mentor, friend and partner @ejasonabel for winning the well deserved Andrew novick award. Outstanding surgeon, scientist, father who has taught me so much. #IKCSNA2025